Skip to content

Inventories at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.1B-2.8%
Bausch + Lomb logo
Bausch + LombBLCO
$977M-5.2%
HRO
HarrowHROW
$16.5M+53.9%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$2.53M-0.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$55M+19.5%
PBH
Prestige Consumer HealthcarePBH
$159.13M+7.7%

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's inventories?
Ocular Therapeutix (OCUL) reported inventories of $3.74M in Q1 2026.
How has Ocular Therapeutix's inventories changed year-over-year?
Ocular Therapeutix's inventories increased by 14.3% year-over-year, from $3.27M to $3.74M.
What is the long-term trend for Ocular Therapeutix's inventories?
Over 5 years (2020 to 2025), Ocular Therapeutix's inventories has grown at a 24.3% compound annual growth rate (CAGR), from $1.2M to $3.56M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.